Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Notice regarding Withdrawal of Shelf Registration Statement for Issuance of New Shares
Notice Regarding Determination of Issue Price, Selling Price and Other Matters
Sumitomo Pharma Plunges on Public Offering Announcement, Dilution Concerns Weigh on Sentiment
Sumitomo Pharma to Raise Up to \116.4 Billion Through Public Offering
Notice Regarding Issuance of New Shares and Secondary Offering of Shares
Notice Regarding Refinancing of Existing Borrowings through a Bridge Loan
Notice Concerning Non-operating Income Recorded in the Company’s Non-consolidated Financial Statements (Japanese GAAP)
Announcement on the Approval for MAA of the Allogeneic iPS Cell-Derived Dopaminergic Neural Progenitor Cell Product “AMCHEPRY” in Japan
Presentation Material (Boost 2028 - Accelerating Strong Sumitomo Pharma -)
Sumitomo Pharma Announces Revisions to Its Financial Forecasts
Announcement of Filing of Shelf Registration Statement for Issuance of New Shares
Sumitomo Pharma Announces Boost 2028 - Accelerating Strong Sumitomo Pharma -
Sumitomo Pharma, Net Income Forecast for the Fiscal Year Revised Upward by 11%, Exceeded Record Profit Forecast
Publication of Materials from the R&D Meeting for Analysts, Investors, and Media
Regarding the Scheduled Review in Japan of the Allogeneic iPS Cell-Derived dopaminergic neural progenitor cells (AMCHEPRY)
Presentation Material (Conference on Q3 FY2025 Financial Results)
Summary of Consolidated Financial Results for the Nine Months Ended December 31, 2025 [IFRS]
Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2026
Sumitomo Pharma, Apr-Dec (Cumulative 3Q) Net Income Increases by 5.1 times, Oct-Dec Net Income Decreases by 84%
Sumitomo Pharma Selected as “Best Website” for the Third Consecutive Year in Both All Markets and Pharmaceuticals Sector Categories